SNX-7081

SNX-7081 is a potent, synthetic small-molecule inhibitor of Heat Shock Protein 90 (Hsp90). It belongs to a class of second-generation Hsp90 inhibitors designed to be more drug-like and potent than first-generation geldanamycin derivatives such as 17-AAG. SNX-7081 functions by binding to the N-terminal ATP-binding pocket of Hsp90, which disrupts the chaperone's ability to fold and stabilize its client proteins. This inhibition leads to the degradation of various oncogenic proteins, including ZAP-70, Akt, and Raf-1, via the ubiquitin-proteasome pathway. Preclinical research has highlighted its potential in treating Chronic Lymphocytic Leukemia (CLL), particularly in cases with TP53 or ATM pathway mutations that are resistant to conventional therapies like fludarabine.